Safe use of radiopharmaceuticals in patients with chronic kidney disease: a systematic review

Schreuder, Nanno; de Romijn, Iris; Jager, Pieter L.; Kosterink, Jos G. W.; van Puijenbroek, Eugène P.

doi:10.1186/s41181-021-00145-w

EJNMMI Radiopharmacy and Chemistry

Table 3 Overview of included studies with their characteristics

From: Safe use of radiopharmaceuticals in patients with chronic kidney disease: a systematic review

References	Year	Study design	Number of patients	Radiopharmaceutical	Indication	Dose (MBq)	Stage of kidney failure (CKD)	Type of dialysis (number of patients)	Timing of dialysis after administration radiopharmaceutical
Akers et al. (2016)	2016	COS	58	[¹⁸F]fludeoxyglucose	PET/CT	370–555	1–5	NA	NA
Aktaş et al. (2008)	2008	CCS	10	[¹³¹I]sodium iodine	TC	1110–3700	5	HD (6); CAPD (4)	24 h continued every day for 5d; CAPD increased from 4 to 6–8 times a day
Alevizaki et al. (2006)	2006	CS	5	[¹³¹I]sodium iodine	PTC	1110–2590	5	HD (4); IPD (1)	48 h, and 2 patients also 96 h
Bhat et al. (2017)	2017	CR	1	[¹³¹I]sodium iodine	PTC	1850	5	HD	15 h, 27 h, 43 h
Courbon et al. (1997)	1997	CR	1	[¹³¹I]sodium iodine	TC	3700	5	HD	2d, 4d
Courbon et al. (2006)	2006	CS	2	[¹³¹I]sodium iodine	TC	3700	5	HD	72 h, 122 h-144 h
Culpepper et al. (1992)	1992	CR	1	[¹³¹I]sodium iodine	FTC	4773	5	HD	24 h,43 h,66 h
Daumerie et al. (1996)	1996	CS	3	[¹³¹I]sodium iodine	PTC	2 treatments of 925	5	HD	2d, 3d
Demko et al. (1998)	1998	CR	1	[¹³¹I]sodium iodine	TMNG	1045.62	5	HD	24 h
Driedger et al. (2006)	2006	CS	3	[¹³¹I]sodium iodine	PTC	3700; 3700; 2500	5	HD (2); CAPD (1)	NA
El-Zeftawy et al. (2017)	2017	CCS	27	[¹³¹I]sodium iodine	DTC	Mean dose 5550	3 and 4	NA	NA
Fofi et al. (2013)	2013	CS	2	[¹³¹I]sodium iodine	PTC	1850	5	CHD	24 h, 48 h
Holst et al. (2005)	2005	CR and TM	1	[¹³¹I]sodium iodine	PTC^a	3637	5	HD	2d, 3d, 4d
Howard and Glasser (1981)	1981	CR	1	[¹³¹I]sodium iodine	PTC	740	5	HD	NA
Jiménez et al. (2001)	2001	CS	3	[¹³¹I]sodium iodine	PTC	2775; 3219; 4440	5	HD	24 h, 48 h, 72 h, 96 h, 144 h
Kaptein et al. (2000)	2000	CS	2	[¹³¹I]sodium iodine	PTC	980; 1110	5	CAPD	3–5 times a day
Kode et al. (2017)	2017	CCS	30	[¹⁸F]fludeoxyglucose	PET/CT	5.18 /kg	4 and 5	NA^b	NA
Laffon et al. (2008)	2008	TM	NA	[¹⁸F]fludeoxyglucose	NA	NA	NA	NA	NA
Magné et al. (2002)	2002	CR	1	[¹³¹I]sodium iodine	PTC	1850	5	HD	24 h, 72 h, 144 h
McKay and Malaroda (2019)	2019	TM	NA	[¹³¹I]sodium iodine^c	TD	NA	5	NA	Several timing intervals were simulated
McKillop et al. (1985)	1985	CR	1	[¹³¹I]sodium iodine	GD	462.5	5	HD	3d
Mello et al. (1994)	1994	CR	1	[¹³¹I]sodium iodine	PTC	2 treatments of 3700	5	HD	41 h, 89 h
Minamimoto et al. (2007)	2007	COS	20	[¹⁸F]fludeoxyglucose	PET/CT	210–360	NA^d	NA	NA
Miyasaka et al. (1997)	1997	CR	1	[¹³¹I]sodium iodine	GD	740	5	HD	24 h
Morrish et al. (1990)	1990	CR	1	[¹³¹I]sodium iodine	PTC	1850; 4440; 5550; 9250	5	HD	48 h, 96 h, 144 h
Pahlka and Sonnad (2006)	2006	TM	NA	[¹³¹I]sodium iodine	TC	NA	5	HD; CAPD	Several timing intervals were simulated
Sinsakul and Ali (2004)	2004	CS	2	[¹³¹I]sodium iodine	PTC	3700; 5809	5	HD	20 h-24 h
Tobes et al. (1989)^e	1989	CCS	1	[¹³¹I]iobenguane	PC	18.5	5	HD	NA
Toriihara et al. (2015)	2015	CCS	24	[¹⁸F]fludeoxyglucose	PET/CT	3.7 /kg	5	HD	NA
Toubert et al. (2001)	2001	CR	1	[¹³¹I]sodium iodine	FTC	814	5	CAPD	4 times a day
Vermandel et al. (2020)	2020	CS	6	[¹³¹I]sodium iodine	TC	1842–3747	5	HD	42 h, 90 h
Wang et al. (2003)	2003	CS	2	[¹³¹I]sodium iodine	PTC	3700; 5550	5	CAPD	4 times a day
Willegaignon et al. (2010)	2010	CR	1	[¹³¹I]sodium iodine	DTC	3700	5	CAPD	NA
Yeyin et al. (2016)	2016	CS	3	[¹³¹I]sodium iodine	DTC	2775 and 1850; 2775; 1850	5	HD	24 h, 48 h

CAPD, continuous ambulatory peritoneal dialysis; CCS, case–control study; CHD, continuous haemodialysis; CKD, chronic kidney diseases; COS, cohort study; CR, case report; CS, case series; DTC, differentiated thyroid cancer; FTC, follicular thyroid cancer; GD, Graves' disease; HD, haemodialysis; IPD, intermittent peritoneal dialysis; NA, not available; PC, pheochromocytoma; PET/CT, positron emission tomography/computed tomography; PTC, papillary thyroid cancer; TC, thyroid cancer; TD, thyroid disease; TM, Theoretical model; TMNG, toxic multinodular goiter
^aAlthough the study describes hyperthyroidism as well, the reported case was treated with [¹³¹I]sodium iodine for thyroid cancer
^b12 patients were on dialysis, type and timing were not specified
^cIn this study a pharmacokinetic software model was developed and validated with data of ¹³¹I, ¹²³I and ¹²⁴I
^dPatients with a blood serum creatinine level > 1.1 mg/dl
^eThe findings in one patient were compared with two patients with mild to moderate renal function

Back to article page